# QUESTION

PROBLEM:	Routes of glucose administration for hypoglycemia
OPTION:	Buccal glucose administration
COMPARISON:	Oral (swallowed) glucose administration
MAIN OUTCOMES:	Resolution of symptoms; Blood/plasma glucose concentrations at 20 min (mg/dL) (Chlup 2009); Increased blood glucose at 20 min (Gunning 1976); Time to resolution of symptoms; Any adverse event; Resolution of hypoglycemia; Time to resolution of hypoglycemia; Ease of administration / administration delay;
SETTING:	First aid setting, healthy volunteers (adults)
PERSPECTIVE:	Perspective of both the hypoglycemia individual and first aid provider
BACKGROUND:	Hypoglycemia is a common problem worldwide. First aid is frequently provided by family, self and lay providers in the form of glucose via tablets or glucose-containing foods and beverages. Some commercial preparations of glucose are directed for use by buccal routes. This could be of benefit in part of the world where parenteral administration of glucose is not feasible, and when hypoglycemic individuals are unable to swallow.
CONFLICT OF INTEREST:	None

## ASSESSMENT

Problem Is the problem a priority?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
o No o Probably no o Probably yes • Yes o Varies o Don't know	<ul> <li>Hypoglycemia is common throughout the world, in both individuals with insulin-dependent and non-insulin dependent diabetes, (1) and is associated with a considerable cost and burden to the health service (2). There can also be substantial consequences for the individual, with an increased risk of morbidity and mortality from severe episodes [3–5].</li> <li>1. Edridge et al. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. IPLoS One. 2015; 10(6): e0126427.</li> <li>2. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabetic medicine: a journal of the British Diabetic Association. 2012;29(7):855–62.</li> <li>3. Feinkohl I, Aung PP, Keller M, Robertson CM, Morling JR, McLachlan S, et al. Severe Hypoglycemia and Cognitive Decline in Older People With Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes care. 2014;37(2):507–15. doi: 10.2337/dc13-1384</li> <li>4. Bloomfield HE, Greer N, Newman D, MacDonald R, Carlyle M, Fitzgerald P, et al. Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes—A Systematic Review of the Evidence. VA Evidence-based Synthesis Program Reports. Washington (DC)2012.</li> </ul>	Hypoglycemia is common; prompt first aid management is needed; routes other than oral need to be explored.

	5. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe Hypoglycemia an Vascular Events and Death. New England Journal of Medicine. 2010;363(15):1410–8. doi:	
Desirable Effects How substantial are the desirable	e anticipated effects?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
o Trivial • Small o Moderate o Large o Varies o Don't know	<ul> <li><u>Desirable effects:</u> There is very little evidence, but it would seem to favor oral administration of glucose (1, 2) We did not identify any evidence to address the critical outcomes of resolution of sympto to resolution of symptoms, and the important outcomes of adverse events, resolution of hypoglycemia, time to resolution of hypoglycemia and treatment delay. Furthermore, the evidence for a significant rise in blood glucose is lacking. The comparison healthy volunteers, and the level of evidence is very low. 1. Chlup R, Zapletalova J, Peterson K, Poljakova I, Lenhartova E, Tancred A, Perera R, Smita of buccal glucose spray, liquid sugars and dextrose tablets on the evolution of plasma gluc concentration in healthy persons. Biomed Pap Med Fac Univ Palacky Olomouc Czech Reputs/153(3):205-209 2. Gunning RR, Garber AJ. Bioactivity of Instant Glucose. Failure of Absorption through Ora JAMA 1978, 240:1611-1612</li></ul>	oms and time in is with al J. Impact cose ub 2009,
Undesirable Effects How substantial are the undesira	ble anticipated effects?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
o Large o Moderate • Small o Trivial o Varies o Don't know	Undesirable effects:         For the critical outcome of blood/plasma glucose concentration at 20 min (mg/dL), we ide harm from buccal glucose administration when compared with oral glucose administration 95%CI, -24.205.80 with an assumed within subjects correlation coefficient of 0.1; P < 0.1 95%CI, -18.0711.93 with an assumed within subjects correlation coefficient of 0.9; P < C	on (MD, -15; .01; MD, -15; 0.01) (1, 2). al J. Impact cose ub 2009,

<b>Certainty of evidence</b> What is the overall certainty of the						
JUDGEMENT	RESEARCH EVIDENC	E				ADDITIONAL CONSIDERATIONS
• Very low • Low • Moderate	Downgrading of evidence	for serious risk of bias,	indirectness and imprecis	ion.		As much research includes healthy individuals or is about bioavailability and not clinical changes, it is difficult to determine if the effects demonstrated would impact on real-world
o High o No included studies	Outcomes	With oral (swallowed) glucose	With buccal glucose	Difference	Relative effect (95% CI)	outcomes.
	resolution of symptoms - not reported	0 per 1.000	<b>0 per 1.000</b> (0 to 0)	<b>0 fewer</b> <b>per</b> <b>1.000</b> (0 fewer to 0 fewer)	2	
	Blood/plasma glucose concentrations at 20 min (mg/dL) (Chlup 2009)	The mean blood/plasma glucose concentrations at 20 min (mg/dL) (Chlup 2009) was <b>112</b> mg/dL	The mean blood/plasma glucose concentrations at 20 min (mg/dL) (Chlup 2009) in the intervention group was 15 mg/dL lower (0 to 0)	MD 15 mg/dL lower (0 to 0 )	-	
	Increased blood glucose at 20 min (Gunning 1976)	1.000 per 1.000	<b>0 per 1.000</b> (0 to 550)	1.000 fewer per 1.000 (1.000 fewer to 450 fewer)	<b>RR</b> 0.00 (0.00 to 0.55)	
	Time to resolution of symptoms - not reported	0 per 1.000	<b>0 per 1.000</b> (0 to 0)	<b>0 fewer</b> <b>per</b> <b>1.000</b> (0 fewer to 0 fewer)	-	
	Any adverse event - not reported	0 per 1.000	<b>0 per 1.000</b> (0 to 0)	0 fewer per	-	

	Resolution of hypoglycemia - not reported	0 per 1.000	<b>0 per 1.000</b> (0 to 0)	1.000 (0 fewer to 0 fewer) 0 fewer per 1.000 (0 fewer to 0	
	Time to resolution of hypoglycemia - not reported	0 per 1.000	<b>0 per 1.000</b> (0 to 0)	fewer) 0 fewer per 1.000 (0 fewer to 0 fewer)	
	Ease of administration / administration delay - not reported	0 per 1.000	<b>0 per 1.000</b> (0 to 0)	0 fewer per 1.000 (0 fewer to 0 fewer)	
Values					
Is there important uncertainty about or variab	lity in how much people value				ADDITIONAL CONSIDERATIONS
<ul> <li>Important uncertainty or variability</li> <li>Possibly important uncertainty or variability</li> <li>Probably no important uncertainty or variability</li> <li>No important uncertainty or variability</li> </ul>	There is only indirect evide	ence as most research		developed countries where	The Task Force agreed that the ability to quickly and effectively manage the individual in the out-of-hospital setting would be desirable and of value.
Balance of effects					
Does the balance between desirable and unde			ison?		ADDITIONAL CONSIDERATIONS
	0			I	

<ul> <li>o Favors the comparison</li> <li>Probably favors the comparison</li> <li>o Does not favor either the intervention or the comparison</li> <li>o Probably favors the intervention</li> <li>o Favors the intervention</li> <li>o Varies</li> <li>o Don't know</li> </ul>	Based on the limited available data regarding buccal administration of glucose, the perceived, potential risk of accidental aspiration may outweigh the very low apparent benefit of buccal glucose.	
Resources required		
How large are the resource requirements (costs	?(	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul> <li>o Large costs</li> <li>o Moderate costs</li> <li>Negligible costs and savings</li> <li>o Moderate savings</li> <li>o Large savings</li> <li>o Varies</li> <li>o Don't know</li> </ul> Certainty of evidence of requ		Cost of glucose tablets is less than 50 cents per 15 gm dose, and for glucose gel is about \$3 per 15 gm dose (US).
What is the certainty of the evidence of resource	e requirements (costs)?	1
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS

<ul> <li>Very low</li> <li>Low</li> <li>Moderate</li> <li>High</li> <li>No included studies</li> </ul>		
<b>Cost effectiveness</b> Does the cost-effectiveness of the intervention	favor the intervention or the comparison?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul> <li>o Favors the comparison</li> <li>Probably favors the comparison</li> <li>o Does not favor either the intervention or the comparison</li> <li>o Probably favors the intervention</li> <li>o Favors the intervention</li> <li>o Varies</li> <li>o No included studies</li> </ul>	The cost effectiveness may favor oral glucose.	For the individual that is conscious and able to swallow, the cost would probably favor the oral route.
<b>Equity</b> What would be the impact on health equity?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
o Reduced o Probably reduced • Probably no impact o Probably increased o Increased o Varies o Don't know	The impact on health equity is uncertain, however, access to a buccal source would be a concern. Glucose sources beyond tablets could be limited in certain parts of the world, thus there may be an increased impact.	There are plausible differences between buccal glucose and oral glucose where oral glucose appears to be less expensive.
Acceptability Is the intervention acceptable to key stakeholde	ers?	

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
o No o Probably no • Probably yes o Yes o Varies o Don't know		
<b>Feasibility</b> Is the intervention feasible to implement?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul> <li>○ No</li> <li>○ Probably no</li> <li>○ Probably yes</li> <li>● Yes</li> <li>○ Varies</li> <li>○ Don't know</li> </ul>		Feasibility may depend on the form of glucose available for use.

# SUMMARY OF JUDGEMENTS

				JUDGEMENT			
PROBLEM	No	Probably no	Probably yes	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	Mu derate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	Very low	Low	Noderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important incertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
RESOURCES REQUIRED	Landecosts	Moderate costs	Negligible costs and savings	Moderate savings	Large savings	Varies	Don't know
CERTAINTY OF EVIDENCE OF REQUIRED RESOURCES	Varylon	Low	Moderate	High			No included studies

	JUDGEMENT								
COST EFFECTIVENESS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention Values	No included studies			
EQUITY	Reduced	Probably reduced	Probably no impact	Probably increased	Increased Varies	Don't know			
ACCEPTABILITY	No	Probably no	Probably yes	Yes	Varies	Don't know			
FEASIBILITY	No	Probably no	Probably yes	Yes	Varies	Don't know			

### **TYPE OF RECOMMENDATION**

option     option or the comparison       O     O	Strong recommendation against the option	Conditional recommendation against the	Conditional recommendation for either the Conditional recommendation for the option	Strong recommendation for the option
		option	option or the comparison	
	0	•	0 0	0



### CONCLUSIONS

#### Recommendation

We recommend against buccal mucosal glucose administration (the option; conditional recommendation) compared with oral glucose administration for individuals with suspected hypoglycemia.

#### Justification

Based on the evidence, buccal administration of glucose is not the preferred option in a person with suspected hypoglycemia who is conscious and able to swallow.



Individuals with suspected hypoglycemia and altered mental status and inability to swallow will probably require advanced medical care.



#### **Implementation considerations**

None.

#### Monitoring and evaluation

Not required.

#### **Research priorities**

Current research regarding the administration of glucose via the buccal route compared with oral (swallowed) glucose tablets is limited both in terms of populations (pediatrics or adults) and in conditions (hypoglycemia associated with diabetes treatment or critical illness).

Randomized controlled trials or large cohort studies are needed to evaluate various outcomes include resolution of symptoms, adverse events and the impact on other health outcomes. These studies should include individuals with diabetes in addition to individuals with hypoglycemia from other causes (e.g. exercise induced, infection, etc).